Profile: Ming Hu

Ming Hu
Ming Hu, Ph.D.
Professor of Pharmaceutics
Department of Pharmacological and Pharmaceutical Sciences
531 Texas Medical Center Campus
1441 Moursund
Houston, TX 77030
832-842-8320 (phone)
832-842-8305 (fax)
mhu@uh.edu

Education

Sabbatical Leave at Laboratory of Metabolism, National Cancer Institute, Bethesda, Maryland

Postdoctoral Training, Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas 

Ph.D. in Pharmaceutics, College of Pharmacy, The University of Michigan, Ann Arbor, Michigan 

B.S. in Pharmacy, Shanghai First Medical College, Shanghai, The People's Republic of China

Research Interests

Bioavailability of drugs, nutrients and micronutrients with emphasis on mechanisms of absorption and metabolism of flavonoids and phenolic drugs

Research Grants

Current Support

NIH R15 AI089671, Clinical Pharmacology of Polymyxin B, 3/1/2010 – 02/28/2013, PI: Vincent Tam (University of Houston), total direct cost per year is $100,000. The direct cost to Ming Hu is $50,000 per year for three years.

NIH 2R01GM070737-0310 National Institute of General Medicine. Disposition of Flavonoids via Metabolic Interplay (competitive renewal). 8/01/09-7/31/13. PI: Ming Hu. The direct cost (all to Hu) is $175,000 ($262,500 total cost) per year for 4 years.

NIH 3R01GM070737-04S1 National Institute of General Medicine.  Supplement to Disposition of Flavonoids via Metabolic Interplay. 8/01/09-7/31/13. PI: Ming Hu. The direct cost ($48,000 to Hu) is $90,000 ($135,000 total cost) per year for 3 years.

NIH 1R01AT005522-0110 National Center for Complementary and Alternative Medicine.  Chemoprevention of lung cancer with red ginseng extracts.  8/01/09-7/31/13. PI: Ming You (Medical College of Wisconsin), Portion to University of Houston (site PI, Hu), approximately $125,000 per year direct cost (or $187,500 total cost) for four years.

Completed Projects (since 2005)

ZinPro Corp. Transport of Amino Acid Metal Complex in the Caco-2 Cell Culture Model 3/1/2011-8/31/2011. PI. M. Hu, $39,518 project direct cost.

NIH 5R21AT004673-02 National Center for Complementary and Alternative Medicine. Phase I Study to Evaluate Safety and Toxicity of EGCG in HIV-1-Infected Subjects.  8/1/2008-7/31/2011, PI. Nance (Baylor College of Medicine), Ming Hu, co-Investigator (Annual direct cost approximately $26,000 a year for three years).

NIH 5R01AT003203 National Center for Complementary and Alternative Medicine.  Chemoprevention of Lung Cancer with Anti-tumor B. 9/30/2007-8/31/2011. PI: Ming You (Medical College of Wisconsin) Ming Hu, co-PI. (Hu’s budget is $125,000 direct cost (or $187,500 total cost) per year, four years.)

ZinPro Corp. Transport of Amino Acid Metal Complex in the Caco-2 Cell Culture Model 10/1/2009-12/31/2010. PI. M. Hu, $26,868 project direct cost.

GCC Pharmacoinformatics Training Grant.  Predicting UGT catalyzed metabolism of flavonoids.  $31,000 per year for two years, July 1, 2007-June 30, 2009.  (M. Hu, Primary Mentor)

Boehringer Ingelheim Pharmaceuticals, Inc.  Characterization of BI Compound Absorption Using A Perfused Rat Intestinal Perfusion Model and Caco-2 Cell Culture Model,  $100,143 for two awards, November 1, 2007-May 31, 2009, Ming Hu, PI

National Institute of General Medical Sciences (R01GM070737), Disposition of Flavonoids via Recycling.  June 1, 2006-May 31, 2008, $298,000, Ming Hu, PI

PDA Foundation.  Effects of Pharmaceutical Processing on the Activity and Stability of siRNA.  $22,500, January 1, 2007-December 31, 2007, Ming Hu, PI

The Gustavus and Louise Pfeiffer Research Foundation.  Biological and Pharmaceutical Considerations in Herbal and Supplemental Product Standardization.  $75,000 a year direct cost starting July 1, 2007.  Ming Hu, PI

University of Houston, GEAR grant, Improve Bioavailability of Phenolics by Decreasing Metabolism, September 1, 2006-August 31, 2007, $30,000

National Cancer Institute (R01CA087779).  Absorption and Metabolism of Isoflavonoids.  July 1, 2002-June 30, 2006.  $890,051.  Ming Hu, PI.

US Pharmacopoeia, Analysis of Red Clover Isoflavone Supplement Products. July 1, 2006-June 30, 2007, $20,000.

US Pharmacopoeia, Red Clover Isoflavones.  July 1, 2005-June 30, 2006, $20,000.

University of Houston, GEAR grant, Limiting Bioavailability of Food-Borne Carcinogens with Flavonoid Supplementation, September 1, 2005-August 31, 2006, $25,000 

Awards & Honors

  • Rho Chi, Pharmacy Honor Society
  • Visiting Professor, University of Valencia, Valencia, Spain (2000)
  • Visiting Professor, National University of Singapore, Singapore (2001)
  • Visiting Professor, Shanghai Institute of Pharmaceutical Industries, Shanghai, China (2003-06
  • Visiting Professor, Jiangsu Academy of Chinese Medicine (2004-present)

Selected Journal Articles

Characterization of Polymyxin B-induced Nephrotoxicity: Implications for Dosing Regimen Design. Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. Antimicrob Agents Chemother. 2012 Sep;56(9):4625-9 doi: 10.1128/AAC.00280-12. Epub 2012 Jun 11. PMID: 22687519

Chemopreventive effect of a mixture of Chinese herbs (antitumor B) on chemically induced oral carcinogenesis. Wang Y, Yao R, Gao S, Wen W, Du Y, Szabo E, Hu M, Lubet RA, and You M. Mol. Carcinogenesis., 2011 Nov 15. doi: 10.1002/mc.20877. ePub Nov 2011 PMID: 22086836

Inhibition of p-glycoprotein leads to improved oral bioavailability of compound k, an anticancer metabolite of red ginseng extract produced by gut microflora. Yang Z, Wang JR, Niu T, Gao S, Yin T, You M, Jiang ZH, and Hu M. Drug Metab Dispos 40:1538-1544, 2012. PMID: 22584255

CYP3A-dependent Drug Metabolism is Reduced in Bacterial Inflammation in Mice. Gandhi, A, Guo T, Shah P, Moorthy B, Chow D, Hu M, and Ghose, R. Br J. Pharmacol. 2012 Aug;166(7):2176-87. doi: 10.1111/j.1476-5381.2012.01933.x. ePub Feb 2012 PMID: 22394353

Systematic Studies of Sulfation and Glucuronidation of 12 Flavonoids in the Mouse Liver S9 Fraction Reveals both Unique and Shared Positional Preferences. Tang L, Yang CH, Zhou J, Xia BJ, Hu M, Liu ZQ J. Agric. Food Chem. 2012 Mar 28;60(12):3223-33. Epub 2012 Mar 15. Epub 2012 Mar 15. PMID: 22352802

SULT1A3-mediated regiospecific 7-O-sulfation of flavonoids in Caco-2 cells can be explained by the relevant molecular docking studies. Meng SN, Wu BJ, Singh R, Yin T, Morrow JK, Zhang S, and Hu M. Mol. Pharm. 2012 Apr 2;9(4):862-73. Epub 2012 Mar 16. PMID: 22352375

Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches. Wu BJ, Singh R, Yin T, Morrow JK, Zhang S, and Hu M. Pharm Res. 2012 Jun;29(6):1544-61. PMID: 22302521

Development and validation of a highly sensitive ULPC-MS/MS method for simultaneous determination of aconitine, mesaconitine, hypaconitine, and five of their metabolites in rat blood and its application to a pharmacokinetic study of aconitine, mesaconitine, and hypaconitine. Ye L, Gao S, Liu W, Yang Z, Hu M and Liu, ZQ. Xenobiotica 2012 Jun;42(6):518-25. doi: 10.3109/00498254.2011.641608. Epub 2011 Dec 22. PMID:22188409

UDP-glucuronosyltransferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP. Jiang W, Xu B, Wu B, Yu R, Hu M, Drug Metab. Disp., 40(2):336-45, 2012. Epub 2011 Nov 9. PMID: 22071170

Evaluation of 3,3’,4’-trihydroxyflavone and 3,6,4’-trihydroxyflavone (4’-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1. Wu B, Zhang SX, Hu M. Mol. Pharm.2011 Dec 5;8(6):2379-89. Epub 2011 Oct 21. PMID: 21985641

Enhancement of oral bioavailability of ginsenoside 20(s)-Rh2 through improved understanding of its absorption and efflux mechanisms. Yang Z, Gao S, Wang J, Yin T, Teng Y, Wu B, You M, Jiang ZH, and Hu M. Drug Metab. Disp., 39:1866-72, 2011. PMID: 21757611

In-vitro potency of various polymyxin B components. Tam VH, Cao H, Ledesma KR, Hu M. Antimicrob Agents Chemother. 2011 Sep;55(9):4490-1. Epub 2011 Jun 27. PMID: 21709096

Regioselective Glucuronidation of Flavonols by Six Human UGT1A Isoforms. Wu B, Xu B, Hu M. Pharm Res. 2011 Aug;28(8):1905-18. Epub 2011 Apr 7. PMID: 21472492

Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein. Ye L, Tao W, Tang L, Liu W, Yang Z, Zhou J, Zheng Z, Cai Z, Hu M, Liu, Z, J. Pharm. Sci. 2011 Nov;100(11):5007-17. doi: 10.1002/jps.22693. Epub 2011 Jun 30. PMID: 21721007

Sulfation of selected mono-hydroxyflavones by sulfotransferases in vitro: a species and gender comparison. Yang CH, Tang L, Lv C, Ye L, Xia BJ, Hu M, Liu ZQ. J Pharm Pharmacol. 2011 Jul; 63 (7) :967-70.

Validated LC-MS/MS method for the determination of maackiain and its sulfate and glucuronide in blood: Application to pharmacokinetic and disposition studies. Gao S, Yang Z, Yin T, You M, Hu M.  J Pharm Biomed Anal. 55(2):288-93, 2011.

Uridine Diphosphate Glucuronosyltransferase Isoform-Dependent Regiospecificity of Glucuronidation of Flavonoids.  Singh R, Wu B, Tang L, Hu M., J. Agric. Food Chem., 59(13):7452-64, 2011

Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein. Ye L, Tao W, Tang L,  Liu W,  Yang Z, Zhou J,  Zheng Z, Cai Z,  Hu M, Liu, Z, J. Pharm. Sci., PMID: 21721007 in press

Regioselective Glucuronidation of Flavonols by Six Human UGT1A Isoforms. Wu B, Xu B, Hu M. Pharm Res. 2011 Apr 7. [Epub ahead of print]

In-vitro potency of various polymyxin B components. Tam VH, Cao H, Ledesma KR, Hu M. Antimicrob Agents Chemother. 55(9):4490-4491, 2011

Enhancement of oral bioavailability of ginsenoside 20(s)-Rh2 through improved understanding of its absorption and efflux mechanisms.   Yang Z,  Gao S, Wang J,  Yin T, Teng Y, Wu B,  You M,  Jiang ZH, and Hu M. Drug Metab. Disp., 2011, in press

Evaluation of 3,3’,4’-trihydroxyflavone and 3,6,4’-trihydroxyflavone (4’-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1. Wu B, Zhang SX, Hu M.  Mol. Pharm., 2011 accepted

Systematic Studies of Sulfation and Glucuronidation of 12 Flavonoids in the Mouse Liver S9 Fraction Reveals both Unique and Shared Positional Preferences. Tang L,  Yang CH, Zhou J,  Xia BJ, Hu M, Liu ZQ J. Agric. Food Chem. 2011 accepted

UGT1A9-overexpressing HeLa Cells Is a Appropriate Tool to Delineate the Kinetic Interplay between BCRP and UGT and to Rapidly Identify the Glucuronide Substrates of BCRP. Jiang W, Xu B, Wu B, Yu R, Hu M, Drug Metab. Disp., 2011 accepted

3D-QSAR Studies on UGT1A9-mediated 3-O-Glucuronidation of Natural Flavonols Using a Pharmacophore-based CoMFA Model.  B. Wu, J. Morrow, R. Singh, S. Zhang, and M. Hu. J Pharmacol Exp Ther. 336(2):403-13, 2011.

Role of intestinal hydrolase in the absorption of prenylated flavonoids present in Yinyanghuo. Chen Y, Wang J, Jia X, Tan X, Hu M. Molecules. 16(2):1336-48, 2011.

Sensitive and robust UPLC-MS/MS method to determine the gender-dependent pharmacokinetics in rats of emodin and its glucuronide. Liu W, Zheng Z, Liu X, Gao S, Ye L, Yang Z, Hu M, Liu Z. J Pharm Biomed Anal. 2011 Apr 5;54(5):1157-62.

Biopharmaceutical and pharmacokinetic characterization of matrine as determined by a sensitive and robust UPLC-MS/MS method.  Zhen Yang, Song Gao, Taijun Yin, Kaustubh H Kulkarnia, Yang Teng, Ming You, and Ming Hu.  J. Pharm. Biomed. Anal., 51(5), 1120-1127, 2010.

Highly Variable Contents of Phenolics in St John’s Wort Products Impact Their Transport in the Human Intestinal Caco-2 Cell Model: Pharmaceutical and Biopharmaceutical Rationale for Product Standardization.  S. Gao, W. Jiang, T. Yin, and M. Hu, J. Agric Food Chem. 58(11):6650-9, 2010.

Simultaneous determination of genistein and its four phase II metabolites in blood by a sensitive and robust UPLC-MS/MS method: application to an oral bioavailability study of genistein in mice. Z. Yang, W. Zhu, S. Gao, H. Xu, B. Wu, R. Singh, L. Tang, K. Kulkarni and M. Hu, J. Pharm. Biomed. Anal. 53(1):81-9, 2010.

Use of Glucuronidation Fingerprinting to Describe and Predict mono- and di- Hydroxyflavone Metabolism by Recombinant UGT Isoforms and Human Intestinal and Liver Microsomes.  L. Tang, L. Ye, R. Singh, B. Wu, C. Lv, J. Zhao, Z. Liu, and M. Hu, Mol. Pharm. 7(3):664-79, 2010

Use of Isoform-Specific UGT Metabolism to Predict Rates and Profiles of Glucuronidation of Wogonin and Oroxylin A by Human Liver and Intestinal Microsomes.  Q. Zhou, Z. Zheng, B. Xia, L. Tang, C. Lv, W. Liu, Z. Liu, and M. Hu. Pharm, Res. 27(8):1568-83, 2010

Species and gender differences affect the metabolism of emodin via glucuronidation, W. Liu, L. Tang, L. Ye, Z. Cai, B. Xia, J. Zhang, M. Hu, Z. Liu, AAPSJ   12(3):424-36, 2010.

Breast Cancer Resistance Protein (Bcrp1) and Sulfotransferases Determine the Disposition of Genistein in Mouse Intestine. W. Zhu, S. W. J. Wang, H. Xu, and M. Hu, AAPS J. 12(4):525-36.  2010

Identification of the Position of Flavonoid O-glucuronidation by Analyzing Shift in Online UV Spectrum (max) Generated from a Diode-arrayed Detector. R. Singh, B. Wu, M. Hu.  J. Agr Food Chem., J Agric Food Chem. 58(17):9384-95, 2010.

The pharmacokinetics of raloxifene and its interaction with apigenin in rat.  Chen Y, Jia X, Chen J, Wang J, Hu M. Molecules. 15(11):8478-87, 2010.

Determination of Osthol and Its Metabolites in a Phase I Reaction System and the Caco-2 Cell Model by HPLC-UV and LC-MS/MS.  Z. Yuan, H. Xu, K. Wang, Z. Zhao, and M. Hu.  J. Pharm. Biomed. Anal., 49(5):1226-32, 2009

Disposition of Flavonoids via Enteric Recycling:  UGT1As Deficiency in Gunn Rats Is Compensated by Increases in UGT2Bs Activities.  S. W.J. Wang, K H. Kulkarni, L. Tang, J. Wang, T. Daidoji, H. Yokota, and M. Hu, J. Pharmacol. Exp. Therap. 329(3):1023-31, 2009

UGT Isoform-Specific Metabolism of Isoflavones: Structural Changes Affect the Position-Specific Metabolism.  L. Tang, R. Singh, X. Liu, and M. Hu, Mol. Pharm. 6(5):1466-82, 2009.

Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells. SB Muralimanoharan, AB Kunnumakkara, B Shylesh, KH Kulkarni, H. Xu, M. Hu, BB Aggarwal, G. Rita, AP Kumar. Prostate. 69(5):494-504, 2009.

Disposition of Naringenin Differs from Apigenin and Is Affected by Compensating Efflux Transporters (MRP2 and BCRP) of Hydrophilic Glucuronides. H. Xu, K. H. Kulkarni, and M. Hu, Mol. Pharm. 6(6):1703-15, 2009.

Variable Isoflavone Contents of Red Clover Products Affect Their Intestinal Disposition  S. W.J. Wang, Y. Chen, T. B. Joseph, M. Hu, J Altern Comp. Med, 14, 287-297, 2008

Intestinal Absorption Mechanisms of Prenylated Flavonoids Present in the Heat-Processed Epimedium koreanum Nakai (Yin Yanghuo). Y. Chen, X. Jia, and M. Hu, Pharm Res. 25, 2190-2199, 2008

In vivo pharmacokinetics of hesperidin are affected by treatment with glucosidase-like BglA protein isolated from yeasts.  Li YM, Li XM, Li GM, Du WC, Zhang J, Li WX, Xu J, Hu M, Zhu Z.  J Agric Food Chem. 56(14):5550-7, 2008.

Determination of the UDP-Glucuronosyltransferase (UGT) Isoforms Responsible for the Metabolism of Flavonoids in Caco-2 TC7 Cells Using Expressed UGTs and siRNA.  X. Liu, V. Tam, and M. Hu, Mol. Pharm. 4(6):873-82, 2007

Disposition of Flavonoids via Enteric Recycling: Enzyme Stability Affects Characterization of Prunetin Glucuronidation across Species, Organs, and UGT Isoforms, T. B. Joseph, S. W.J. Wang, X. Liu, J. Wang, K, H. Kulkarni, H. Xu, and M. Hu  Mol Pharm.  4(6):883-94, 2007

Books, Book Chapters & Reviews

Books

Oral Bioavailability: Basic Principles, Advanced Concepts and Applications (Hu M and Li XL editors, 1st Ed.). July, 2011

Book Chapters & Reviews (since 2004)

Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways. Jiang, W and Hu, M. RSC Adv., 2012, 2, 7948-7963

Bioavailability and Pharmacokinetics of Genistein: Mechanistic Studies on its ADME. Yang Z, Kulkarni K, Zhu W, Hu M. Anticancer Agents Med Chem. 2012 May 2. PMID: 22583407

Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes. Dong D, Ako R, Hu M, Wu B. Xenobiotica. 2012 Mar 2 PMID: 22385482

Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Dong D, Wu B, Chow D, Hu M. Drug Metab Rev. 2012 Jan 18 PMID:22251142

Caco-2 Cell Culture Model for Oral Drug Absorption. K Kulkarni and M Hu , in “Oral Bioavailability: Basic Principles, Advanced Concepts and Applications (Hu M and Li XL editors, 1st Ed.). July, 2011

Amino Acid Drug Transporters. Z. Liu and M. Hu, in “Oral Bioavailability: Basic Principles, Advanced Concepts and Applications (Hu M and Li XL editors, 1st Ed.). July, 2011

Drug Metabolism in Gastrointestinal Track. R. Singh and M. Hu, in “Oral Bioavailability: Basic Principles, Advanced Concepts and Applications (Hu M and Li XL editors, 1st Ed.). July, 2011

Barriers to Oral Bioavailability: An Overview. M. Hu and X. Li, in “Oral Bioavailability: Basic Principles, Advanced Concepts and Applications (Hu M and Li XL editors, 1st Ed.). July, 2011

Regioselective Sulfation and Glucuronidation of Phenolics: Insights into the Structural Basis of Conjugation. Wu B, Basu D, Meng S, Wang X, Zhang S, Hu M. Curr Drug Metab. 12(9):900-16, 2011 PMID: 21933112

First-pass metabolism via UDP-glucuronosyltransferases: a barrier to oral bioavailability of phenolics. B. Wu, K. Kulkarnia, S. Zhang, M. Hu, J. Pharm. Sci., 100(9):3655-81, 2011 PMID: 21484808

Bioavailability Challenges Associated with Development of Anti-Cancer Phenolics. S. Gao, M. Hu, Mini Rev Med Chem. 10 (6): 550-567, 2010

Oral Absorption Basics: Pathways, Physicochemical and Biological Factors, and Methods of Study. Z. Liu, S. W.J. Wang, and M. Hu in “Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice” (Y. Qiu, Y. Chen, G. G.Z. Zhang, L. Liu, W. Porter Eds.), Academic Press, 2008

Commentary: Bioavailability of Flavonoids and Polyphenols: Call to Arms, M. Hu, Mol Pharm. 4(6):803-6, 2007

Natural Polyphenol Disposition via Coupled Metabolic Pathways. Z. Liu, M. Hu, Expert Opinion in Drug Metabolism, 3, 389-406, 2007

Coupling of Conjugating Enzymes and Efflux Transporters: Impact on Bioavailability and Drug Interaction, E.J. Jeong, X. Liu, X. Jia. J. Chen, M. Hu. Curr. Drug Metab., 6, 455-468, 2005

In Situ Single-Pass Perfused Rat Intestinal Model for Absorption and Metabolism. E. J. Jeong, Y. Liu, H. Lin, M. Hu, in “Optimization in Drug Discovery: In Vitro Methods” (Z. Yan and GW Caldwell eds.) Humana Press, pp.69-76, 2004

The Use of Caco-2 Cell Monolayers to Study Drug Absorption and Metabolism. M. Hu, J. Lin, H. Lin, J. Chen, in “Optimization in Drug Discovery: In Vitro Methods” (Z. Yan and GW Caldwell eds.) Humana Press, pp.19-35, 2004

Invited Presentations & Lectures

Dual Roles of BCRP in Disposition of Flavonoids and Chemopreventive Phenolics. Mechanism Based Natural Product Development Conference. Vancouver, British Columbia, Canada (2012)

Development of Wudang-Based Herbal Drugs for Lung Cancer Prevention and Treatment. Hubei University of Medicine, Shiyan, Hubei, China (2012)

Ginsenosides and Gut Microbiome: Mutually Beneficial Interactions? Peking University Centennial Lecture Series, Beijing, China (2012)

Manipulating Intestinal Microbiome for Bioavailability Improvement. Macau University of Science and Technology, Macau, China (2012)

Marching Toward Prediction of Glucuronidation of Phenolics In Vivo. University of Michigan, College of Pharmacy, Ann Arbor, Michigan, USA (2012)

Prediction of Glucuronidation Promises, Progresses and Problems. China Pharmaceutical University, Nanjing, China (2012)

Manipulating Intestinal Microbiome By Chinese Medicinal Herbs. Jiangsu Academy of Traditional Chinese Medicine, Nanjing, Jiangsu, China (2012)

Computational Modeling of UGT for Better Prediction of Its Functionality and Structure. Controlled Release Society, China Section, Shanghai, China (2011)

Computational Modeling of UGT for Better Prediction of Its Functionality and Structure. China Medical University, Shenyang, China (2011)

In Search of Herbal-Based Chemopreventive Agents. Hainan Haikou Hospital, Haikou, Hainan, China (2011)

Computational Modeling of UGT for Better Prediction of Its Functionality and Structure. Shenyang Pharmaceutical University, Shenyang, China (2011)

Platforms to Evaluate Flavonoid Bioavailability, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming. China (2010)

Biological Barriers to Flavonoid Bioavailability, Rutgers University College of Pharmacy, Piscataway, NJ (2010)

Biological Barriers to Flavonoid Bioavailability, Ohio State University College of Pharmacy, Columbus, OH (2010)

Biological Barriers to Flavonoid Bioavailability, Medical College of Wisconsin, Milwaukee, WI (2010)

Biological Barriers to Flavonoid Bioavailability, Beijing University College of Pharmacy, Beijing, China (2010)

Bioavailability Challenges of Flavonoids and Polyphenols, Materia Medica, Chinese Academy of Medical Sciences, Beijing, China (2009)

Biopharmaceutical Considerations in Developing Sustained Release Formulations.  Boehringer Ingelheim Pharmaceutical Incorporated, Ridgefield, Connecticut (2009)

Biopharmaceutical Considerations in Oral Drug Delivery, HD Biosciences, Shanghai, China (2009)

Biopharmaceutical Challenges Associated with Development of Naturally Occurring Chemopreventive Polyphenols, Jiangsu Province of Traditional Chinese Medicine, Nanjing, Jiangsu, China (2008)

Introduction to Chemoprevention: From Bedside to Lab and Back to the Patients, Jiangsu Province of Traditional Chinese Medicine, Nanjing, Jiangsu, China (2008)

Bioavailability Barrier Network of Flavonoids, Tianjin University of Chinese Medicine, Tianjin, China (2008)

Biopharmaceutical Challenges Associated with Development of Naturally Occurring Chemopreventive Polyphenols, Shengyang Pharmaceutical University, Shengyang, China (2008)

Regulation of Disposition Pathways Impacts Oral Drug Bioavailability and Bioequivalence, National Defense Medical Center, Taipei, China (2007)

Bioavailability Barrier Networks of Flavonoids and Polyphenols, National Defense Medical Center, Taipei, China (2007)

Herbal Product Standardization Regulatory and Biopharmaceutical Considerations.  ACPA 7th International Conference, Nanjing, China (2007)

Challenges in Searching for New Drugs at Developed Economies: Opportunities for Chinese Pharmaceutical Companies, Guangzhou Pharmaceuticals, Ltd., Guangzhou, China (2007)

Molecular/Physiological Mechanisms Behind Oral Drug Pharmacokinetics, Southern Medical University, Guangzhou, China (2007)

Bioavailability Barrier Networks of Flavonoids and Polyphenols, Unilever China, Ltd.  Shanghai, China (2007)

Do Tofu, Vegetables, Fruits and Wine Have What We Need to Avoid Medicines?  SCBA-Texas Chapter Seminar, Houston, Texas (2007)

Challenges Facing Development of Poorly Bioavailable Chemopreventive Polyphenols.  Hormel Institute, University of Minnesota, Minnesota (2007)

Challenges Associated with Oral Delivery of Drugs.  Fujian Pharmaceutical Association, Fuzhou, Fujian, China (2007)

Flavonoids:  Good Stuff Come in Small Quantities?  The Methodist Hospital, Texas Medical Center, Houston, TX (2007)

Contributed Presentations

Effects of Breast Cancer Resistance Protein (BCRP) on the Disposition of Wogonin in Caco-2 cells, Engineered HeLa cells and FVB mice. Wen Jiang and Ming Hu. AAPS Annual Meeting and Exposition, Washington D.C. (2011)

Role of UGT1A and Mrp2 on pharmacokinetics and disposition of genistein in rats following oral administration. Kaustubh Kulkarni, Zhen yang, Tao Niu, Song Gao and Ming Hu. AAPS Annual Meeting and Exposition, New Orleans, LA. (2011)

Characterization of Stepwise Metabolism of Ginsenosides Rb1 in Mouse Intestinal Microbiota. Tao Niu, Song Gao, Zhen Yang, Ming Hu. AAPS Annual Meeting and Exposition, Washington DC. (2011)

Comparison of Resokaempferol metabolism by selected Human UGTs and relevant Plant UGTs. Sumit Basu, Baojian Wu, Ming Hu. AAPS Annual Meeting and Exposition, Washington D.C. (2011)

Evaluation of 3,3’,4’-trihydroxyflavone and 3,6,4’-trihydroxyflavone (4‘-O-glucuronidation) as the in vitro functional marker for hepatic UGT1A1. Baojian Wu, Shuxing Zhang, Ming Hu. AAPS Annual Meeting and Exposition, Washington DC. (2011)

Role of p-glycoprotein in the efflux of ginsenosides in Caco-2 cells and MDR1 knockout mice. Zhen Yang, Song Gao, Taijin Yin, Jingrong Wang, Zhihong Jiang, Ming Hu. AAPS Annual Meeting and Exposition, Washington, D.C. (2011)

Isoform-specific Regiospecificity and Substrate-selectivity of UGT1A1, UGT1A8 and UGT1A9 in Glucuronidating Flavonoids. Rashim Singh, Lan Tang, Baojian Wu and Ming Hu. AAPS Annual Meeting and Exposition, New Orleans (2010)

Efflux Transporters Play Rate-limiting Role in the Excretion of Glucuronides of Flavones but not Flavonols in the Caco-2 Cell Culture Model. Rashim Singh, Baojian Wu, Lan Tang and Ming Hu. AAPS Annual Meeting and Exposition, New Orleans (2010)

Establishment, Characterization and Application of Stable HeLa Cells overexpressing UGT1A9. Wen Jiang, Beibei Xu and Ming Hu. AAPS Annual Meeting and Exposition, New Orleans, LA. (2010)

Oral Bioavailability of total genistein: gender and ovary effect. Kaustubh Kulkarni Zhen Yang, Tao Niu and Ming Hu. AAPS Annual Meeting and Exposition, New Orleans, LA. (2010).

Construction of 3-OH specific models using pharmacophore-based CoMFA to predict glucuronidation of flavonols. Baojian Wu, Rashim Singh, Shuxing Zhang, Ming Hu. AAPS Annual Meeting and Exposition, New Orleans, LA. (2010)

Role of p-glycoprotein in the transport of 20(s)-ginsenoside Rh2 in Caco-2 and MDR1-MDCKII cells. Zhen Yang, Song Gao, Taijin Yin, Jingrong Wang, Zhihong Jiang, Ming Hu. AAPS Annual Meeting and Exposition, New Orleans, LA. (2010)

Study on metabolism of flavonoids and excretion of flavonoid glucuronides by using UGT1A9 -Overexpressing HeLa Cells. Wen Jiang, Lan Tang and Ming Hu. AAPS Annual Meeting and Exhibition, Los Angeles, CA (2009)

Effect of breast cancer resistance protein (BCRP/ABCG2) on the in vivo pharmacokinetic study of genistein and its four metabolites in mice. Zhen Yang, Song Gao, Wei Zhu, Haiyan Xu, Yang Teng, Ming Hu. AAPS Annual Meeting and Exposition, Los Angeles, CA. (2009)

Prediction of Disposition of Flavonoids in Caco-2 Cells using their Rates of Glucuronidation by Human Recombinant UGT Isoforms. Rashim Singh, Baojian Wu, Lan Tang and Ming Hu. AAPS Annual Meeting and Exhibition, Los Angeles, CA (2009)

Pharmacophore and 3-D QSAR In-silico Modeling of Glucuronidation of Flavonoid by UGT1A8. Rashim Singh, Baojian Wu, Lan Tang, James Briggs and Ming Hu. AAPS Annual Meeting and Exhibition, Los Angeles, CA (2009)

Role of Estrogen in Absorption and Disposition of Daidzein in Male and Female Wistar Rats. K Kulkarni, M Hu. AAPS Annual Meeting and Exposition, Los Angeles, CA (2009).

Role of Gender in Absorption and Disposition of Genistein in Male and Female Sprague Dawley Rats. K Kulkarni, M Hu. AAPS Annual Meeting and Exposition. Los Angeles CA (2009)

Biological and Pharmaceutical Considerations in Herbal and Supplemental Product Standardization. Song Gao, Wen Jiang, and Ming Hu. 15th North American Meeting of International Society for the Study of Xenobiotics, San Diego, CA (2008)

Rapid and Simultaneous Determination of Docetaxel, Paclitaxel, Irinotecan, Methotrexate, and Matrine by Liquid Chromatography-tandem Mass Spectrometry. Zhen Yang, Haiyan Xu, Ming Hu. 15th North American Meeting of International Society for the Study of Xenobiotics, San Diego, CA (2008).

Effect of Structural Changes on the Isoform-Specific Glucuronidation of Six Isoflavones by Recombinant Human UGT Isoforms. Lan Tang, Rashim Singh, Ming Hu. 15th North American Meeting of International Society for the Study of Xenobiotics, San Diego, CA (2008).

Correlation between the Rates of Metabolism of Flavonoids by Recombinant Human UGT Isoforms and Caco-2 Cell Culture Model. Rashim Singh and Ming Hu. AAPS Annual Meeting and Exposition, Atlanta, GA (2008).

Generation of UGT Isoform-specific Pharmacophores to Predict Metabolism of Flavonoids. Rashim Singh R, James Briggs and Ming Hu. 18th Keck Center Annual Research Conference, Houston, TX (2008)

Effect of Structure on the Transport of Flavonoids in Caco-2 Cell Culture Model. Rashim Singh and Ming Hu. 15th North American Meeting of International Society for the Study of Xenobiotics, San Diego, CA (2008)

Metabolism of Flavonoids and Excretion of Flavonoid Glucuronides inUGT1A9-Overexpressing HeLa cells. Wen Jiang, Lan Tang and Ming Hu. 15th North American Meeting of International Society for the Study of Xenobiotics, San Diego, CA (2008)

Effect of different concentrations of sodium taurocholate on cholesterol transport in Caco-2 cell model. Kaustubh Kulkarni, Haiyan Xu and Ming Hu. 15th North American Meeting of International Society for the Study of Xenobiotics, San Diego, CA (2008).

Development and validation of UPLC-MS/MS method for cholesterol transport in Caco-2 cell culture model. Kaustubh Kulkarni, Haiyan Xu and Ming Hu. American Association of Pharmaceutical Scientists Annual Meeting, Atlanta, GA (2008).

Disposition of Genistein and Genistin in the Perfused Mouse Intestinal Model. Etta Meraji, Wei Zhu, Ming Hu. Association of Pharmaceutical Scientists Annual Meeting, San Diego, CA (2007).

Breast Cancer Resistance Protein (BCRP/ABCG2) Excretes the Phase II Metabolites of Genistein and Apigenin in Mouse Intestine. Wei Zhu, Haiyan Xu and Ming Hu. American Association of Pharmaceutical Scientists Annual Meeting, San Diego, CA (2007).

Effect of Number and Position of Hydroxyl group on the Metabolism of Flavonoids by Expressed Human UGT Isoforms. Rashim Singh and Ming Hu. American Association of Pharmaceutical Sciences Annual Meeting and Exposition, San Diego, CA (2007).

Prediction of Flavonoids Metabolism by UDP-glucuronosyltransferases Enzyme. Rashim Singh, James M. Briggs and Ming Hu. 17th Keck Center Annual Research Conference, League City, TX (2007).

Gender Difference Affects Metabolism of Isoflavones in Rat Intestinal and Liver Microsomes. Kaustubh Kulkarni, Stephen Wang and Ming Hu. American Association of Pharmaceutical Scientists Annual Meeting San Diego, CA (2007)

Editorial Appointments

  • Editorial Board Member, Molecular Pharmaceutics
  • Editorial Board Member, Journal of Alternative and Complementary Medicine
  • Editorial Board Member, Drug Metabolism Letters
  • Editorial Board Member, Chinese Journal of Pharmaceutical Sciences
  • Journal Reviewer (ad hoc): Molecular Pharmacology, Journal of Pharmacology and Experimental Therapeutics, Pharmaceutical Research, Drug Metabolism and Disposition, Journal of Pharmaceutical Sciences, European Journal of Pharmaceutical Sciences, International Journal of Pharmaceutics, Carcinogenesis, Gastroenterology, Biochemical Pharmacology, Comparative Biochemistry and Physiology, Life Science, Current Drugs Ltd, American Chemical Society Book Series

Affiliations & Service

Affiliations/Memberships

  • American Society of Pharmacology and Experimental Therapeutics
  • American Association of Pharmaceutical Scientists
  • American Chemical Society

Grant Reviewer

  • National Science Foundation of China, Reviewer, Key Projects in Pharmacology and Pharmaceutics (2005, 2006)
  • National Science Foundation of China, Council Member, Pharmacology and Pharmaceutics (2005, 2006)
  • National Institute of Ageing.  P01 Grant Review, University of Illinois at Champaign-Urbana (2004)
  • National Cancer Institute, Small Grant Program in Cancer Prevention (2003)
  • National Cancer Institute, NCI FLAIR program (PA-01-091) (2003)
  • National Institutes of Health, Chemo/Dietary Prevention Study Section (ad hoc 2003-2005) (Permanent 2005-2008)
  • National Institutes of Health, Metabolic Pathology Study Section (ad hoc member 2003)
  • National Cancer Institute: Special Emphasis Panel (RFA-CA-03-003) Molecular Targets for Nutrients in Prostate Cancer Prevention (Nov. 2002)
  • National Science Foundation (May 2002)
  • U.S. Civilian Research and Development Foundation (2001)
  • American Institute of Biological Sciences (1992, 1994)